echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Bayer, Fosun, Zejing...Who is competing for the first-line targeted therapy market for liver cancer?

    Bayer, Fosun, Zejing...Who is competing for the first-line targeted therapy market for liver cancer?

    • Last Update: 2021-07-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


















    Reference materials:


    Insight database: "Advanced liver cancer, the guide recommends these targeted drugs and immunotherapies"


    Mi Nei.
    com: "[Heavyweight] Chia Tai Tianqing Will Take the First Imitation of Lenvatinib"


    Daily Economic News: "Fosun Pharmaceutical's new drug clinical trial approved by 2026, the market size of first-line liver cancer targeted drugs may exceed 10 billion"

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.